Please set your featured image
Science Park Tenant Prosensa Announces Further Alliance With GlaxoSmithKline
Prosensa, the innovative Dutch bio-pharmaceutical company with a UK office at Begbroke Science Park, has announced the initiation of two further programmes with GlaxoSmithKline covering novel RNA-based treatments for Duchenne Muscular Dystrophy, a severely debilitating childhood muscular disease that affects 1 in 3,500 new-born boys.
The two new programmes will address the development of four compounds which target different patients suffering from DMD, and confirm the joint commitment of both companies to find treatments for this disease. Prosensa and GlaxoSmithKline are now engaged in comprehensive clinical programmes to fully understand how the compounds impact on individuals. Prosensa moved in to office space in the Centre for Innovation and Enterprise on Begbroke Science Park earlier this year. The decision, Dr Giles Campion, Chief Medical Officer at Prosensa, says “made sense, given the links already established between the University and the company.”
Dr Campion comments “We don’t have a lot of infrastructure within the UK, so it was great to be able to utilise the conference facilities available at Begbroke Science Park to bring key individuals from GlaxoSmithKline and the academic and patient community together earlier in the year. Ultimately we can’t predict how the business will grow. Although we currently only need office space within the Centre for Innovation and Enterprise, if laboratory space were required in the future then we know we are in the right place to be able to expand.”